BDNF and Cerebellar Ataxia

Title:BDNF and Cerebellar Ataxia

Volume: 16 Issue: 3

Author(s): Robert Lalonde*, Magali Hernandez and Catherine Strazielle

Affiliation:

• Université de Lorraine, Laboratoire Stress, Immunité, Pathogènes EA 7300, Campus Santé, 9 avenue de la Forêt de Haye, 54500 Vandoeuvre-les-Nancy, France

Keywords: Neurotrophin, cerebellar development, spinocerebellar ataxia, Friedreich’s ataxia, cerebellar mutants, rotarod.

Abstract: Brain-derived neurotrophic factor (BDNF) has been proposed as a treatment for neurodegeneration, including diseases of the cerebellum, where BDNF levels or those of its main receptor, TrkB, are often diminished relative to controls, thereby serving as replacement therapy. Experimental evidence indicates that BDNF signaling countered cerebellar degeneration, sensorimotor deficits, or both, in transgenic ATXN1 mice mutated for ataxin-1, Cacna1a knock-in mice mutated for ataxin-6, mice injected with lentivectors encoding RNA sequences against human FXN into the cerebellar cortex, Kcnj6^Wv (Weaver) mutant mice with granule cell degeneration, and rats with olivocerebellar transaction, similar to a BDNF-overexpressing transgenic line interbred with Cacng2^stg mutant mice. In this regard, this study discusses whether BDNF is effective in cerebellar pathologies where BDNF levels are normal and whether it is effective in cases with combined cerebellar and basal ganglia damage.

Cite this article as:

Lalonde Robert*, Hernandez Magali and Strazielle Catherine, BDNF and Cerebellar Ataxia, Current Drug Research Reviews 2024; 16 (3) . https://dx.doi.org/10.2174/2589977515666230811093021